Findings

What do systematic reviews say?

2,510 questions · 2,653 findings · 194 reviews · Gynaecology and Fertility

Sort:Best matchNewestHighest certainty Download CSV

No studies found 531 · 20%GRADE not reported 76 · 2.9%Very low 826 · 31.1%Low 855 · 32.2%Moderate 341 · 12.9%High 24 · 0.9%

Intervention not reported

Pain: Acupuncture versus no treatment · women with primary dysmenorrhoea

1 finding from 1 review

Acupuncture for dysmenorrhoea 2016 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 384 participants
Low

Intervention not reported

Adverse events: Acupuncture versus no treatment · women with primary dysmenorrhoea

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for dysmenorrhoea 2016 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Pain: Acupressure versus sham or placebo control · women with primary dysmenorrhoea

1 finding from 1 review

Acupuncture for dysmenorrhoea 2016 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 538 participants
Low

Intervention not reported

Pain: Acupressure versus NSAIDs · women with primary dysmenorrhoea

It is very uncertain whether the intervention changes pain: Acupressure versus NSAIDs (very low certainty).

1 finding from 1 review

Acupuncture for dysmenorrhoea 2016 · Cochrane Headline outcomes only
MD 0.39
1 study · 136 participants
Very low

Intervention not reported

Pain score: Acupressure versus no treatment · women with primary dysmenorrhoea

It is very uncertain whether the intervention changes pain score: Acupressure versus no treatment (very low certainty).

1 finding from 1 review

Acupuncture for dysmenorrhoea 2016 · Cochrane Headline outcomes only
MD 0.96
2 studies · 140 participants
Very low

Tibolone vs placebo

Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms

Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.33 [0.27, 0.41]
5 studies · 842 participants
Moderate

Tibolone vs combined HT

Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms

Tibolone probably leads to lower unscheduled bleeding (all doses) compared with combined HT (moderate certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.32 [0.24, 0.41]
16 studies · 6438 participants
Moderate

Tibolone vs combined HT

Endometrial cancer · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.47 [0.23, 9.33]
5 studies · 3689 participants
Very low

Tibolone vs combined HT

Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.69 [0.78, 3.67]
5 studies · 4835 participants
Very low

Tibolone vs combined HT

Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation; all doses) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.44 [0.09, 2.14]
4 studies · 4529 participants
Very low

Tibolone vs combined HT

Cardiovascular events · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes cardiovascular events (all doses) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.63 [0.24, 1.66]
2 studies · 3794 participants
Very low

Tibolone vs combined HT

Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes cerebrovascular event (all doses) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.76 [0.16, 3.66]
4 studies · 4562 participants
Very low

Tibolone vs combined HT

Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 3.05 [0.12, 75.2]
2 studies · 970 participants
Very low

Tibolone vs placebo

Endometrial cancer · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 2.04 [0.79, 5.24]
9 studies · 8504 participants
Very low

Tibolone vs placebo

Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.52 [0.21, 1.25]
4 studies · 5500 participants
Very low

Tibolone vs placebo

Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms

Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 2.79 [2.1, 3.7]
9 studies · 7814 participants
Moderate

Tibolone vs placebo

Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 0.85 [0.37, 1.97]
5 studies · 9176 participants
Very low

Tibolone vs placebo

Cardiovascular events · postmenopausal women with or without vasomotor symptoms

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 8401 participants
Very low

Tibolone vs placebo

Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms

It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.74 [0.99, 3.04]
4 studies · 7930 participants
Very low

Tibolone vs placebo

Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms

Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).

1 finding from 1 review

Short‐term and long‐term effects of tibolone in postmenopausal women 2016 · Cochrane Headline outcomes only
OR 1.06 [0.79, 1.41]
4 studies · 8242 participants
Low